Home · Health · Sep 11 archive
How Did a Heart Drug With So Much Promise Fall So Flat?
Confirmed
In Short: Experts warn that the premature availability of fake versions of the experimental weight-loss drug retatrutide could jeopardize its development, highlighting the risks involved in clinical trials.
Experts have told the BBC that this is one of the first times they have seen copycat versions of an experimental drug, still in the Phase III testing stage, become so widely available. This raises concerns about the safety and efficacy of the drug, especially as trial participants need to meet strict criteria before being given the real drug or a placebo.
Tom, a participant who accidentally took eight times the recommended dose of a fake version of retatrutide, nearly ended up in hospital, underscoring the potential dangers of these counterfeit drugs. The high rate of failure for drugs in this stage of testing is primarily due to issues that arise when drugs are tested on larger, more diverse populations or reveal unexpected safety hazards.
The excitement around retatrutide has turned into a headache for Eli Lilly, the pharmaceutical company behind it, and regulators in the UK and around the world. Only 50% of drugs in this phase of testing in the US are eventually approved by the Food and Drug Administration (FDA), so there is no guarantee that retatrutide will ever hit the market.
The premature availability of fake versions of retatrutide could jeopardize its development, as it may skew data and compromise the integrity of clinical trials. This highlights the critical need for strict regulation and vigilance in the management of experimental drugs during clinical trials.
What's confirmed
- Experts have told the BBC that this is one of the first times they have seen copycat versions of an experimental drug, still in the Phase III testing stage, become so widely available. This raises concerns about the safety and efficacy of the drug, especially as trial participants need to meet strict criteria before being given the real drug or a placebo.
- Tom, a participant who accidentally took eight times the recommended dose of a fake version of retatrutide, nearly ended up in hospital, underscoring the potential dangers of these counterfeit drugs. The high rate of failure for drugs in this stage of testing is primarily due to issues that arise when drugs are tested on larger, more diverse populations or reveal unexpected safety hazards.
- The excitement around retatrutide has turned into a headache for Eli Lilly, the pharmaceutical company behind it, and regulators in the UK and around the world. Only 50% of drugs in this phase of testing in the US are eventually approved by the Food and Drug Administration (FDA), so there is no guarantee that retatrutide will ever hit the market.
- The premature availability of fake versions of retatrutide could jeopardize its development, as it may skew data and compromise the integrity of clinical trials. This highlights the critical need for strict regulation and vigilance in the management of experimental drugs during clinical trials.
What's still developing
- Test your knowledge with our new weekday mini crossword By Matthew Herper, Jason Mast, and Angus Chen Matthew Herper covers medical innovation — both its promise and its perils.
- Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community.
- At an off-site leadership meeting held by Moderna in March 2023 — after mid-stage results of the biotech company’s cancer vaccine showed promise — CEO Stéphane Bancel had the floor.
- They were compared with 36,927 matched men who had used no drug from the same family.
- A late-stage clinical trial found that, when combined with an SMN2-targeting drug, Isembyld caused young patients’ motor skills to improve after a year, while those in a placebo group declined, a difference that was statistically significant.
- Scholar Rock on Friday received Food and Drug Administration approval for the first-ever therapy that targets the loss of muscle in spinal muscle atrophy, raising hopes that patients with the rare neurological disorder might have a better chance of moving and walking independently.
- The FDA approved the drug, Isembyld, for use in adults and children 2 years and older who are currently receiving SMA therapies that target SMN2, a key gene for neurons that control movement.